Who is sponsoring NCT05959590?

NCT05959590 is sponsored by University of New Mexico.

What condition does NCT05959590 study?

NCT05959590 studies Osteomyelitis.

What drugs are being tested in NCT05959590?

Interventions: Ferumoxides 11.2Mg Solution for Injection.

What is the status of NCT05959590?

NCT05959590 is currently COMPLETED.

Last reviewed 2023-07-25 · How we verify

Ferumoxytol-enhanced Imaging of Osteomyelitis

NCT05959590 PHASE1 COMPLETED

Diabetic foot infections contribute to 75,000 hospitalizations in the US each year. There is a lifetime incidence of 15-25% of foot infections in diabetics. The investigators hypothesize that ferumoxytol (FDA approved for use in CKD patients, unlike gadolinium) will improve the accuracy of MR imaging in the diagnosis of osteomyelitis by allowing for the specific imaging of macrophages that have taken up the iron-based compound. In this study the investigators will image 12 patients with suspected diabetic osteomyelitis using ferumoxytol-contrasted MRI, and evaluate the feasibility of this approach.

Details

Lead sponsor	University of New Mexico
Phase	PHASE1
Status	COMPLETED
Enrolment	12
Start date	Wed Feb 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Osteomyelitis

Interventions

Ferumoxides 11.2Mg Solution for Injection

Countries

United States